CompletedNCT03201757

Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831

This study is completed. It focuses on schizophrenia and currently lists study information in Austria, Bulgaria, Ireland, Israel, Italy, Poland, the United States, Russian Federation, Serbia, South Korea, Ukraine, and the United Kingdom.

SchizophreniaOtherFrom 16 Years to 70 Years

In plain English

Key information made simple

This study exists to understand how this type of care holds up over time after the earliest research stage. Researchers are trying to understand how people respond to this type of care in practice and what may need to be adjusted. For people living with Schizophrenia, the gap between what sounds good on paper and what works in daily life is often important. If the findings are useful, they could help future care become more targeted, practical, and easier to trust. Taking part helps build the evidence that can improve understanding and care for others over time.

What to expect

Your next step

The official record suggests in-person participation through a research setting, with sites including Alkermes Investigational Site in Little Rock, Alkermes Investigational Site in Rogers, and Alkermes Investigational Site in Anaheim. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually being able to understand the study and consent and being able to follow the planned visits or tasks, while common reasons not to take part include active substance or alcohol problems that could affect the results and pregnancy or breastfeeding. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Open source record

Need help deciding?

Ask HopeStage to review this study with me

This form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.

Study reference: NCT03201757. We only ask for your email here. HopeStage can help you review the study, but this is not a medical eligibility decision.

In practice

For you

Taking part may give access to a new approach being evaluated.

It requires regular visits and structured follow-up.

Requires travel, with in-person participation in Austria.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

Study clarity

Things to check before joining

Sponsor: Alkermes, Inc.
Sponsor type: Other organization
Main activity: observational follow-up
Time commitment: long follow-up or multiple visits
Study phase: Not available
Enrollment: Not available
Recruitment status: Completed
Source: Official registry link

FAQ

Questions about this study

What is Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831?

This study is exploring observational follow-up for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.

Who is behind this study, and what type of sponsor is it?

This study is sponsored by Alkermes, Inc.. Based on the sponsor name or official registry information, it appears to be another type of organization. You should verify the details in the official registry record.

What does participation involve, what phase is it, and what should I ask about safety?

This study may involve observational follow-up, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.

Where can I verify the study details?

Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.